Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
AxoGen, Inc. AXGN
$9.19
+$0.02 (0.22%)
На 18:00, 12 мая 2023
Ранг: 2
Ключевые показатели
-
Marketcap
401129700.00000000
-
week52high
13.66
-
week52low
7.20
-
Revenue
138584000
-
P/E TTM
-14
-
Beta
0.62352900
-
EPS
-0.66000000
-
Last Dividend
1.10172300
-
Next Earnings Date
09 мая 2023 г. в 12:00
Описание компании
AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and Avive Soft Tissue Membrane, a processed human umbilical cord membrane that can be used as a resorbable soft tissue covering to separate tissues in the surgical bed. In addition, the company offers AxoTouch two point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. It provides its products to hospitals, surgery centers, and military hospitals plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons in the United States, Canada, Germany, the United Kingdom and other European countries, South Korea, and internationally. AxoGen, Inc. is headquartered in Alachua, Florida.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Canaccord Genuity | Buy | Hold | 09 мая 2022 г. |
| SVB Leerink | Outperform | Outperform | 05 мая 2022 г. |
| JMP Securities | Market Outperform | Market Outperform | 04 ноя 2021 г. |
| Canaccord Genuity | Hold | Hold | 06 мая 2021 г. |
| SVB Leerink | Outperform | Outperform | 23 февр 2021 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Покожие компании
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| MARIANI PETER J | D | 0 | 20940 | 01 февр 2023 г. |
| MARIANI PETER J | D | 61945 | 14550 | 01 февр 2023 г. |
| MARIANI PETER J | A | 76495 | 20940 | 01 февр 2023 г. |
| MARIANI PETER J | D | 20940 | 20939 | 31 янв 2023 г. |
| MARIANI PETER J | D | 55555 | 14320 | 31 янв 2023 г. |
| MARIANI PETER J | A | 69875 | 20939 | 31 янв 2023 г. |
| MARIANI PETER J | D | 41879 | 20939 | 30 янв 2023 г. |
| MARIANI PETER J | D | 48936 | 14111 | 30 янв 2023 г. |
| MARIANI PETER J | A | 63047 | 20939 | 30 янв 2023 г. |
| MARIANI PETER J | D | 62818 | 20940 | 27 янв 2023 г. |
Новостная лента
Axogen, Inc. to report first quarter 2023 financial results and host conference call on May 9, 2023
GlobeNewsWire
18 апр 2023 г. в 16:05
ALACHUA, Fla. and TAMPA, Fla., April 18, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report first quarter 2023 financial results on Tuesday, May 9, 2023 before the market opens. Axogen management will host an investment-community conference call and webcast at 8:00 a.m. ET following the release.
Axogen, Inc. to report fourth quarter 2022 financial results and host conference call on March 14, 2023
GlobeNewsWire
02 мар 2023 г. в 16:00
ALACHUA, Fla. and TAMPA, Fla., March 02, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report fourth quarter 2022 financial results on Tuesday, March 14, 2023 before the market opens. Axogen management will host an investment-community conference call and webcast at 8:00 a.m. ET following the release.
Here's Why "Trend" Investors Would Love Betting on AxoGen (AXGN)
Zacks Investment Research
11 ноя 2022 г. в 10:32
If you are looking for stocks that are well positioned to maintain their recent uptrend, AxoGen (AXGN) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
AxoGen, Inc. (AXGN) Q3 2022 Earnings Call Transcript
Seeking Alpha
08 ноя 2022 г. в 10:40
AxoGen, Inc. (NASDAQ:AXGN ) Q3 2022 Earnings Conference Call November 8, 2022 8:00 AM ET Company Participants Ed Joyce - Director, IR Karen Zaderej - Chairman, CEO & President Pete Mariani - EVP & CFO Conference Call Participants Mike Sarcone - Jefferies Chris Pasquale - Nephron Ryan Zimmerman - BTIG Kyle Rose - Canaccord Genuity Ross Osborn - Cantor Fitzgerald Dave Turkaly - JMP Operator Welcome to the AxoGen Third Quarter 2022 Conference Call. At this time, all participants are in a listen-only mode.
AxoGen (AXGN) Reports Q3 Loss, Tops Revenue Estimates
Zacks Investment Research
08 ноя 2022 г. в 09:48
AxoGen (AXGN) delivered earnings and revenue surprises of 93.33% and 2.38%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?